Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Cephalosporin Market Heading Into 2029?

In recent times, the cephalosporin market has experienced a consistent increase in size. It is projected to expand from $17.69 billion in 2024 to $18.15 billion in 2025, representing a compound annual growth rate (CAGR) of 2.6%. This historical growth trend can be linked to the escalating occurrence of bacterial infections, the surge in antibiotic resistance, an increase in surgical procedures and hospital admissions, heightened consciousness amongst healthcare providers, and regulatory encouragement for the development of antibiotics.

The size of the cephalosporin market is anticipated to consistently expand in the coming years. It is projected to reach “$20.6 billion in 2029 with a compound annual growth rate (CAGR) of 3.2%.” The predicted growth during this forecast period can be credited to the escalating worldwide burden of infectious diseases, burgeoning bacterial resistance, the ongoing expansion in surgical interventions and infections associated with healthcare, the increased need for broad-spectrum antibiotics, and changes in reimbursement policies affecting market dynamics. Key trends to watch in this forecast period are technological advancements, alterations in regulatory landscapes, market growth through advanced solutions, and collaborations and partnerships.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13402&type=smp

Which Factors Are Pushing The Cephalosporin Market Forward?

An expected surge in infectious diseases incidents is forecasted to substantially boost the cephalosporin market’s expansion. Pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites, cause infectious diseases by invading and multiplying, which can spread from person to person, causing diseases like tuberculosis, malaria, and flu. The rise in infectious diseases results in an increased demand for cephalosporin antibiotics, regularly employed to treat bacterial pathogen-induced infectious ailments due to their significant role in controlling and battling bacterial infections. In March 2023, for example, the US-based national public health body, the Centers for Disease Control and Prevention, reported 8,300 tuberculosis (TB) cases in the United States for the year 2022, marking an increase from 7,874 cases in 2021. Consequently, the escalating prevalence of infectious diseases is anticipated to fuel the growth of the cephalosporin market.

The cephalosporin market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Route Of Administration: Injection, Oral

3) By Application: Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Other Applications

Subsegments:

1) By Flat Panel Detector: Active Matrix Flat Panel Detectors, Thin-Film Transistor (TFT) Flat Panel Detectors

2) By Image Intensifier: Single-Field Image Intensifiers, Dual-Field Image Intensifiers

3) By Other Product Type: Charge-Coupled Device (CCD), Complementary Metal-Oxide-Semiconductor (CMOS)

What Trends Are Currently Influencing Growth In The Cephalosporin Market?

Prominent businesses in the cephalosporin market are prioritizing the development of new products and therapies, such as sophisticated cephalosporins, in order to combat antibiotic resistance and improve their portfolio’s ability to tackle a broader range of bacterial infections. Ceftobiprole, a wide-spectrum cephalosporin antibiotic, is employed in treating diverse bacterial infections, including infections affecting the skin and soft tissues, in addition to pneumonia. In July 2022, for example, Mast Group Ltd., a manufacturer and distributor of clinical and industrial diagnostic products based in the UK, rolled out Ceftobiprole 5µg as part of the MASTDISCS Antimicrobial Susceptibility Test line. Ceftobiprole (also known as Zevtera or Mabelio) is a 5th-generation broad-spectrum cephalosporin approved in numerous European nations for treating community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Owing to its wide activity scope, potency against methicillin-resistant Staphylococcus aureus (MRSA), and suitable safety profile, Ceftobiprole is considered a viable substitute for targeted empirical therapy.

Which Organizations Are Driving Progress In The Cephalosporin Industry?

Major companies operating in the cephalosporin market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan PLC, Baxter International Inc., Eisai Co. Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Shionogi & Co Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Lupin Ltd., Zydus Lifesciences Ltd., Alkem Labs Ltd., Aurobindo Pharma Ltd., Fresenius Kabi, Aristo Pharmaceuticals Ltd., Accord Healthcare Ltd., Mankind Pharma Ltd., Qilu Anti Pharmaceutical Co. Ltd., Shandong Ruiying Pioneer Pharmaceutical Co. Ltd., Vansen Pharma Inc.

https://www.thebusinessresearchcompany.com/report/cephalosporin-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Cephalosporin Industry?

Asia-Pacific was the largest region in the cephalosporin market in 2024. The regions covered in the cephalosporin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13402&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model